{"product_id":"vcanbio-bcg-matrix","title":"Vcanbio Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eSee Vcanbio’s product lineup mapped into Stars, Cash Cows, Dogs and Question Marks — a fast, visual way to spot winners and drains. This snapshot hints at where to double down, divest, or experiment; the full BCG Matrix gives you quadrant-by-quadrant data, tailored strategic moves, and ready-to-use Word and Excel files. Skip the guesswork—purchase the complete report for clear, actionable guidance you can present and implement immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCAR-T\/CAR-NK therapy lines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFast-growing oncology cell therapy market exceeded $7.4B in 2024 with ~22% CAGR, and Vcanbio’s CAR-T\/CAR-NK programs are showing tangible clinical traction in local trials. They lead domestically but scale-up and pivotal studies will burn substantial cash. Keeping share and chasing regulatory wins can make these programs the company’s revenue engine. Prioritize manufacturing scale-up and pivotal data to lock leadership.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGene editing platform + hospital partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStrong IP plus embedded clinical partners give Vcanbio both share and speed, with the global gene editing market valued at about 6.46 billion USD in 2023 and forecasted to grow at ~14% CAGR, driving heavy funding needs in 2024. Keep the platform sticky via tooling, assays and workflows to defend the lead. Sustained clinical and commercial wins here convert into durable cash flow later.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCell therapy CDMO (GMP suites)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCell therapy CDMO (GMP suites) is a Stars segment: pipeline demand is rising fast and Vcanbio reports capacity booked with a \u0026gt;12–24 month backlog, driving utilization above 90% and strong pricing power. Recognized quality and high switching costs favor client retention. Expansions, validations, and tech transfers require heavy upfront capital and protracted CAPEX payback. Protect backlog, prioritize high-margin clients, and scale with disciplined capex and pricing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStem-cell clinical applications in Tier‑1 centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAdoption of stem-cell clinical applications is accelerating in select indications where Vcanbio is at point of care; global cell therapy market reached an estimated USD 12.6 billion in 2024, with advanced centers reporting double-digit annual uptake in cardiac and orthopedic indications. Clinical evidence and KOL backing drive share but require ongoing trial support and real-world outcomes; tight outcomes data and active reimbursement engagement (coverage pilots in 8 payors in 2024) are critical. Leadership today becomes the standard tomorrow.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTier‑1 presence: point‑of‑care access\u003c\/li\u003e\n\u003cli\u003eEvidence: KOLs + ongoing trials\u003c\/li\u003e\n\u003cli\u003eOutcomes: tight, continuous RWE\u003c\/li\u003e\n\u003cli\u003eReimbursement: maintain payer pilots (8 in 2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision cell analytics (QC + release assays)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePrecision cell analytics sits in Stars: rapid growth driven by regulatory scrutiny and therapy complexity—global cell and gene therapy market was about $12.5B in 2023 with ~21% CAGR projected through 2030, boosting demand for QC and release assays. Vcanbio’s integrated analytics complement its manufacturing footprint, creating per-batch stickiness. Capital-hungry validation and equipment investments (often millions per site) cement high switching costs and enable land-and-expand across every client batch to sustain the lead.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket: $12.5B (2023), ~21% CAGR to 2030\u003c\/li\u003e\n\u003cli\u003eCapEx: validation\/equipment typically millions per site\u003c\/li\u003e\n\u003cli\u003eStrategy: per-batch land-and-expand drives recurring revenue and client lock-in\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology CAR-T: market ~\u003cstrong\u003e$7.4B\u003c\/strong\u003e (2024), \u003cstrong\u003e22%\u003c\/strong\u003e CAGR — capital hungry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars: oncology CAR-T\/CAR-NK driving growth—oncology cell therapy market ~$7.4B in 2024, ~22% CAGR; pivotal trials and scale-up require heavy cash.\u003c\/p\u003e\n\u003cp\u003eStrong IP and gene-editing tailwinds (global $6.46B in 2023, ~14% CAGR) accelerate platform value but need sustained funding.\u003c\/p\u003e\n\u003cp\u003eCDMO utilization \u0026gt;90% with 12–24m backlog; capex-heavy expansions.\u003c\/p\u003e\n\u003cp\u003eStem-cell adoption and payer pilots (8 in 2024) boost near-term commercialization.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024 Metric\u003c\/th\u003e\n\u003cth\u003eKey\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology CAR-T\u003c\/td\u003e\n\u003ctd\u003e$7.4B; 22% CAGR\u003c\/td\u003e\n\u003ctd\u003eScale\/pivotal focus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;90% util; 12–24m backlog\u003c\/td\u003e\n\u003ctd\u003eHigh pricing power\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStem-cell\u003c\/td\u003e\n\u003ctd\u003e$12.6B market\u003c\/td\u003e\n\u003ctd\u003e8 payer pilots\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix review of Vcanbio’s portfolio, with quadrant strategies, investment recommendations and trend-driven risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Vcanbio BCG Matrix that highlights unit performance fast, so leadership stops guessing and makes confident decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStem cell banking subscriptions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStem cell banking subscriptions sit in a mature category with industry-reported global market size around USD 5 billion in 2024 and high retention—industry benchmarks commonly exceed 80%—delivering predictable recurring cash flow for Vcanbio.\u003c\/p\u003e\n\u003cp\u003eVcanbio’s brand trust and expanding network coverage in China secure meaningful market share per 2024 sector reports, reducing promotional pressure and allowing focus on operations efficiency and margin preservation.\u003c\/p\u003e\n\u003cp\u003eWith low acquisition churn, management can milk steady margins while cross-selling clinical add‑ons and diagnostics to raise lifetime value and incremental ARPU. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCryo logistics and storage services (B2B)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCryo logistics and storage services for hospitals and labs show stable, predictable revenue as operations are anchored by multi-year contracts (typically 3–7 years) and recurring specimen flows, fitting the Cash Cow profile. Profitability is driven by utilization and route density—margins rise sharply as fleet fill rates and consolidation improve. Incremental capital deployed to increase capacity and route efficiency yields higher return on invested capital than chasing new markets. Maintain tight SLAs and disciplined pricing to protect margin and cash generation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQC reagents and release kits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQC reagents and release kits generate steady, recurring orders from existing clients and Vcanbio’s internal plants, creating reliable cash flows. Growth is low but gross margins remain high and the products are defensible due to validation lock‑in with customers. Incremental SKU refreshes sustain relevance and purchase frequency. Cash generated funds R\u0026amp;D and investment in new modalities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTraining and certification programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTraining and certification programs leverage deep institutional relationships and repeat cohorts, with the global corporate training market valued at about $400B in 2024; content is built once and delivery scales cheaply, driving gross margins near 60% and strong ecosystem control.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInstitutional partnerships\u003c\/li\u003e\n\u003cli\u003eHigh cohort repeat rates\u003c\/li\u003e\n\u003cli\u003eLimited competition in niche certifications\u003c\/li\u003e\n\u003cli\u003eScalable content, 60% margin\u003c\/li\u003e\n\u003cli\u003eMaintain accreditation, bundle services\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCell processing consumables (house-brand)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCell processing consumables (house-brand) are true cash cows: every run requires them and validated specs create strong stickiness, supporting stable volumes and solid margins with minimal marketing spend. Focus on procurement efficiencies and expanding private-label SKUs to increase per-run cash yield and lower COGS pressure.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh repeat usage\u003c\/li\u003e\n\u003cli\u003eSpecification lock-in\u003c\/li\u003e\n\u003cli\u003eLow marketing needed\u003c\/li\u003e\n\u003cli\u003eProcurement optimization ups yield\u003c\/li\u003e\n\u003cli\u003ePrivate-label breadth drives margin\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e\n\u003cstrong\u003eUSD 5B\u003c\/strong\u003e stem cell market — \u003cstrong\u003e\u0026gt;80%\u003c\/strong\u003e retention, recurring cash from cryo logistics \u0026amp; reagents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStem cell banking is a USD 5B (2024) mature market with \u0026gt;80% retention, delivering predictable recurring cash flow; cryo logistics and storage (multi-year contracts) and house-brand consumables drive high utilization and margin; QC reagents and training yield steady, high-margin cash that funds R\u0026amp;D and new modalities.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024 Rev (est)\u003c\/th\u003e\n\u003cth\u003eRetention\u003c\/th\u003e\n\u003cth\u003eGross Margin\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStem cell banking\u003c\/td\u003e\n\u003ctd\u003e~$5B market\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;80%\u003c\/td\u003e\n\u003ctd\u003e40–55%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCryo logistics\u003c\/td\u003e\n\u003ctd\u003eMulti-yr contracts\u003c\/td\u003e\n\u003ctd\u003e90%+\u003c\/td\u003e\n\u003ctd\u003e35–50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQC reagents\u003c\/td\u003e\n\u003ctd\u003eStable orders\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003e60–70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTraining\u003c\/td\u003e\n\u003ctd\u003eCorporate market $400B\u003c\/td\u003e\n\u003ctd\u003eRepeat cohorts\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Transparency, Always\u003c\/span\u003e\u003cbr\u003eVcanbio BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact BCG Matrix report you'll receive after purchase. No watermarks, no demo content—just a fully formatted, editable, presentation-ready document. Crafted by strategy experts, it’s ready to download, print, or present immediately. No surprises, no extra edits needed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55674736083321,"sku":"vcanbio-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/vcanbio-bcg-matrix.png?v=1755794323","url":"https:\/\/portersfiveforce.com\/products\/vcanbio-bcg-matrix","provider":"Porter's Five Forces","version":"1.0","type":"link"}